Harvard Bioscience Inc. (HBIO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Harvard Bioscience, Inc. is a developer and manufacturer of technologies for life science applications, including research, drug discovery, and bioproduction. This report covers the quarterly period ended June 30, 2025. The Company operates as a single segment with global sales to academic, government, and pharmaceutical customers.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value (in thousands) | YoY Change |
|---|---|---|
| Revenues | $42,224 | -11.3% vs. $47,609 |
| Gross Profit | $23,717 | -15.3% vs. $27,990 |
| Gross Margin | 56.2% | Down from 58.8% |
| Net Loss | $(52,622) | Worsened from $(7,621) |
| Operating Cash Flow | $5,741 | Improved from $557 |
| Cash and Equivalents | $7,442 | Up from $4,108 |
| Total Debt | $34,864 | Down from $36,956 |
| Stockholders' Equity | $15,733 | Down from $63,340 |
Material Changes and Unusual Items
- Goodwill Impairment: The Company recorded a non-cash goodwill impairment charge of $47.95 million in Q1 2025 due to a sustained decrease in stock price, liquidity risks, and macroeconomic conditions. This charge is the primary driver of the significant net loss for the six-month period.
- Revenue Decline: Revenues decreased 11.3% year-over-year, attributed to softening demand from academic institutions and CROs, as well as the impact of reciprocal tariffs.
- Cost Reductions: Operating expenses decreased significantly (Sales & Marketing down 15.8%, G&A down 18.9%, R&D down 18.2%) primarily due to reduced compensation costs and restructuring efforts.
- ERTC Refunds: The Company received $2.2 million in Employee Retention Tax Credit (ERTC) refunds during the period, which positively impacted operating cash flow.
Outlook, Risks, and Contingencies
- Going Concern Doubt: Management has expressed substantial doubt about the Company's ability to continue as a going concern for at least 12 months. This is due to the inability to meet debt obligations and fund operations without accessing new capital or extending repayment terms.
- Debt Covenant Waivers: As of June 30, 2025, the Company was not in compliance with refinancing milestones and financial covenants. On August 8, 2025, lenders granted a waiver (August 2025 Amendment) contingent on the Company achieving refinancing or repayment steps by December 5, 2025. Failure to do so constitutes an event of default.
- Interest Rate Increase: The August 2025 Amendment increased the interest rate margin to SOFR plus 700 basis points.
- Nasdaq Compliance: The Company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00). It has until October 1, 2025, to regain compliance, potentially requiring a reverse stock split.
- Internal Controls: Material weaknesses in internal controls over financial reporting (order-to-cash and inventory counts) remain unremediated as of June 30, 2025.
Investor Verification Checklist
- Verify the status of the December 5, 2025 refinancing deadline and any progress on securing new capital.
- Monitor the stock price relative to the $1.00 Nasdaq minimum bid price requirement and potential reverse stock split announcements.
- Review the liquidity position given the "substantial doubt" disclosure and the increased interest rate margin on existing debt.
- Assess the sustainability of revenue trends amidst ongoing tariff impacts and reduced government funding for research.
- Confirm the timeline for remediation of material weaknesses in internal controls over financial reporting.